• Explore /
  • Poster
  • / Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

Abstract Poster

Authors

null

Marc Ychou

Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France

Marc Ychou , Michel Rivoire , Simon Thezenas , Rosine Guimbaud , Francois Ghiringhelli , Anne Mercier Blas , Laurent Mineur , Eric Francois , Faiza Khemissa , Marion Chauvenet , Yves Bécouarn , Philippe Houyau , Thomas Aparicio , Marie Pierre Galais , Franck Audemar , Eric Assenat , Antoine Adenis , Claire Jouffroy-Zeller , Rene Adam , Olivier Bouche

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01442935

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3535)

DOI

10.1200/JCO.2018.36.15_suppl.3535

Abstract #

3535

Poster Bd #

28

Abstract Disclosures

Similar Posters

First Author: Evelyne Lopez-Crapez

First Author: Wu Zhang

First Author: Valerie Boige

First Author: Yu Sunakawa